CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015)
CytomX Therapeutics' (CTMX) quarterly Non-Current Debt came in at $78000.0 in Q4 2015, down 95.03% YoY from $1.6 million in Q4 2014, and down 95.03% on a QoQ basis from $1.6 million in Q4 2014.
CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015) Analysis & Trends
CytomX Therapeutics (CTMX) has 2 years of Non-Current Debt data on file, last reported at $78000.0 in Q4 2015.
- Quarterly Non-Current Debt fell 95.03% year-over-year to $78000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $78000.0 (down 95.03% YoY) and the FY2015 annual result came in at $78000.0, down 95.03% from the prior year.
- Non-Current Debt fell to $78000.0 in Q4 2015, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.6 million in Q4 2014 to a low of $78000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 78,000.00 |
| Dec 31, 2014 | 1.57 Mn |